Lipid nanoparticles have been around for decades, but they took a spotlight in the delivery of the COVID19 mRNA-based vaccines. This chemical cage can fuse with cell membranes and deliver a specific payload to a cell. While the delivery to specific cells is routine, are there ways to improve the system to have more specific therapeutic benefit. Dr. John Lewis of Entos discusses lipid nanoparticle chemistry and new formulations that exhibit enhanced capacity to target specific locations and deliver payloads more effectively. We also discuss the current therapies that may benefit from the new technologies.